Logo image of ACST

ACASTI PHARMA INC (ACST) Stock Fundamental Analysis

NASDAQ:ACST - Nasdaq - CA00430K8656 - Common Stock - Currency: USD

3.37  -0.03 (-0.88%)

After market: 3.38 +0.01 (+0.3%)

Fundamental Rating

3

ACST gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ACST as it has an excellent financial health rating, but there are worries on the profitability. ACST has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACST had negative earnings in the past year.
In the past year ACST has reported a negative cash flow from operations.
ACST had negative earnings in each of the past 5 years.
ACST had a negative operating cash flow in each of the past 5 years.
ACST Yearly Net Income VS EBIT VS OCF VS FCFACST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

ACST has a Return On Assets of -16.41%. This is in the better half of the industry: ACST outperforms 65.98% of its industry peers.
ACST has a better Return On Equity (-19.28%) than 73.20% of its industry peers.
Industry RankSector Rank
ROA -16.41%
ROE -19.28%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ACST Yearly ROA, ROE, ROICACST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACST Yearly Profit, Operating, Gross MarginsACST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

ACST has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACST has more shares outstanding
ACST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACST Yearly Shares OutstandingACST Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ACST Yearly Total Debt VS Total AssetsACST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -2.64, we must say that ACST is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ACST (-2.64) is comparable to the rest of the industry.
ACST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.64
ROIC/WACCN/A
WACCN/A
ACST Yearly LT Debt VS Equity VS FCFACST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

ACST has a Current Ratio of 7.86. This indicates that ACST is financially healthy and has no problem in meeting its short term obligations.
ACST has a better Current ratio (7.86) than 78.35% of its industry peers.
ACST has a Quick Ratio of 7.86. This indicates that ACST is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACST (7.86) is better than 78.87% of its industry peers.
Industry RankSector Rank
Current Ratio 7.86
Quick Ratio 7.86
ACST Yearly Current Assets VS Current LiabilitesACST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

ACST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.32%, which is quite impressive.
EPS 1Y (TTM)78.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACST will show a very strong growth in Earnings Per Share. The EPS will grow by 22.76% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.02%
EPS Next 2Y4.97%
EPS Next 3Y24.24%
EPS Next 5Y22.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACST Yearly Revenue VS EstimatesACST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2021 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
ACST Yearly EPS VS EstimatesACST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ACST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACST Price Earnings VS Forward Price EarningsACST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACST Per share dataACST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as ACST's earnings are expected to grow with 24.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.97%
EPS Next 3Y24.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACASTI PHARMA INC

NASDAQ:ACST (10/25/2024, 8:22:28 PM)

After market: 3.38 +0.01 (+0.3%)

3.37

-0.03 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-09 2024-08-09/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners20.9%
Inst Owner Change90.53%
Ins Owners53.95%
Ins Owner Change0%
Market Cap34.17M
Analysts82.86
Price Target8.16 (142.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.19%
Min EPS beat(2)-6.26%
Max EPS beat(2)62.63%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-69.34%
Max EPS beat(4)62.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-42.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 3.38
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS5.85
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.41%
ROE -19.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.86
Quick Ratio 7.86
Altman-Z -2.64
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.66%
EPS Next Y-11.02%
EPS Next 2Y4.97%
EPS Next 3Y24.24%
EPS Next 5Y22.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.69%
OCF growth 3YN/A
OCF growth 5YN/A